Contents | Page(s) | |
Strategic report | 1 - 10 | |
Directors' report | 11 - 12 | |
Independent auditors' report | 13 - 16 | |
Income statement | 17 | |
Statement of comprehensive income | 17 | |
Balance sheet | 18 | |
Statement of changes in equity | 19 | |
Notes to the financial statements | 20 - 36 |
Financial performance | 2025 | 2024 |
$'000 | $'000 | |
Earnings | ||
(Loss)/Profit for the financial year | ( | |
Capital and Balance Sheet | ||
Total assets | ||
Total liabilities | ( | ( |
Total equity |
Balance sheet categories | 31 December 2025 |
Non- TCP | |
$'000 | |
Assets | |
Debtors | |
Cash and cash equivalents | |
77,767 |
Balance sheet categories | 31 December 2024 |
Non- TCP | |
$'000 | |
Assets | |
Debtors | |
Cash and cash equivalents | |
43,646 |
Gross balance sheet exposure1 | Assets captured by market risk | Net balance sheet exposure | Net balance sheet exposure held with: | |||
JPMorgan Chase undertakings | External counter parties | |||||
$'000 | $'000 | $'000 | $'000 | $'000 | ||
At 31 December 2025 | ||||||
Financial assets: | ||||||
Financial assets held at fair value through profit or loss | ( | 33 | — | |||
Debtors | — | 1,337 | 7,483 | |||
Cash and cash equivalents | — | 75,898 | 19 | |||
Total | (33,897) | 84,770 | 77,268 | 7,502 | ||
Gross balance sheet exposure1 | Assets captured by market risk | Net balance sheet exposure | Net balance sheet exposure held with: | |||
JPMorgan Chase undertakings | External counter parties | |||||
$'000 | $'000 | $'000 | $'000 | $'000 | ||
At 31 December 2024 | ||||||
Financial assets: | ||||||
Financial assets held at fair value through profit or loss | ( | 111 | 17 | |||
Debtors | — | 14,405 | 4,118 | 10,287 | ||
Cash and cash equivalents | — | 37,634 | — | |||
Total | (94,183) | 52,167 | 41,863 | 10,304 | ||
2025 | 2024 | At 31 December | ||||||||
Avg. | Min | Max | Avg. | Min | Max | 2025 | 2024 | |||
$'000 | $'000 | $'000 | $'000 | $'000 | $'000 | $'000 | $'000 | |||
95 % VaR | 749 | 482 | 1,002 | 1,205 | 354 | 2,095 | 905 | 606 | ||
Director | |
Director | |
Director | |
Director |
for and on behalf of | |
Chartered Accountants and Statutory Auditors | |
For the year ended 31 December | 2025 | 2024 | |
Note | $'000 | $'000 | |
Operating income | 5 | ||
Administrative expenses | 6 | ( | ( |
Impairment loss on Investment in JPMorganChase undertakings | 12 | ( | — |
Other (expense)/income | 7 | ( | |
Operating (loss)/profit | ( | ||
Interest and similar income | 8 | ||
Interest and similar expense | 9 | ( | ( |
(Loss)/Profit before taxation | ( | ||
Tax (credit)/charge | 11 | ( | |
(Loss)/Profit for the financial year | ( |
As at 31 December | 2025 | 2024 | |
Note | $'000 | $'000 | |
Current assets | |||
Financial assets held at fair value through profit or loss | 15 | ||
Debtors | 14 | ||
Cash and cash equivalents | 16 | ||
Total current assets | |||
Total assets | |||
Current liabilities | |||
Financial liabilities held at fair value through profit or loss | 17 | ( | ( |
Creditors and provisions | 18 | ( | ( |
Total current liabilities | ( | ( | |
Net current assets | |||
Net assets | |||
Equity | |||
Share capital | 19 | ||
Retained earnings | |||
Total equity |
Notes | Share capital | Retained earnings | Total equity | |
$'000 | $'000 | $'000 | ||
Balance as at 1 January 2024 | ||||
Profit for the financial year | — | |||
Dividend paid(1) | 20 | — | ( | ( |
Balance as at 31 December 2024 | ||||
Loss for the financial year | — | ( | ( | |
Balance as at 31 December 2025 |
EMEA | AMERICAS | APAC | Total | |||||
2025 | 2024 | 2025 | 2024 | 2025 | 2024 | 2025 | 2024 | |
$'000 | $'000 | $'000 | $'000 | $'000 | $'000 | $'000 | $'000 | |
Interest income | — | — | — | — | ||||
Total assets | ||||||||
2025 | 2024 | |
$'000 | $'000 | |
Trading profit | ||
Interest income on financial assets held at fair value through profit or loss | ||
Other operating (expense)/income | ( | |
2025 | 2024 | |
$'000 | $'000 | |
Auditors' remuneration for the audit of the Company's annual financial statements(1) | ||
Custodian fees | ||
Legal and professional fees | ||
Other administrative expenses | ||
2025 | 2024 | |
$'000 | $'000 | |
Foreign exchange translation (loss)/gain | ( |
2025 | 2024 | |
$’000 | $’000 | |
Interest and similar income from other JPMorganChase undertakings |
2025 | 2024 | |
$’000 | $’000 | |
Interest and similar expenses from other JPMorganChase undertakings |
2025 | 2024 | |
$'000 | $'000 | |
Aggregate emoluments | ||
Total contributions to a defined contribution plan* | ||
Number of Directors with shares received or receivable under LTIPs | ||
Number of Directors to whom defined contribution pension rights accrued |
2025 | 2024 | |
$'000 | $'000 | |
(a) Analysis of tax (credit)/charge for the year | ||
Current tax: | ||
Current tax on profits for the year | ( | |
Total tax (credited)/charged to income statement for the year | ( |
2025 | 2024 | |
$'000 | $'000 | |
(Loss)/Profit before taxation | ( | |
Tax (credit)/charge based on the standard United Kingdom corporation tax rate of 25% (2024: 25%) | ( | |
Recurring items: | ||
Deductions not allowable for tax purposes | ||
Non-taxable foreign exchange | ( | — |
Tax (credit)/charge for the year | ( |
Name | Registered address | Holding | Shares held % |
CAFM | Regus Business Centre, Nexsky Building, 7th Floor Ebene Cybercity, 72201 Mauritius | Direct | 100.00 |
BAFM | Regus Business Centre, Nexsky Building, 7th Floor Ebene Cybercity, 72201 Mauritius | Direct | 100.00 |
2025 | |
Company investment in other JPMorganChase undertakings | $'000 |
At 1 January | — |
Add: Capital contribution in subsidiary | 400 |
Less: Impairment loss on Investment in JPMorganChase undertakings | (400) |
At 31 December | — |
Interest in unconsolidated structured entities | |||
Fair value of assets held by SPE | Financial assets and Liabilities at fair value through profit and loss | Total | |
31 December 2025 | $'000 | $'000 | $'000 |
Other | — | — | — |
Maximum exposure to loss | — | — | — |
Total liabilities | — | — | — |
Interest in unconsolidated structured entities | |||
Fair value of assets held by SPE | Financial assets and Liabilities at fair value through profit and loss | Total | |
31 December 2024 | $'000 | $'000 | $'000 |
Other | 895,787 | 5,757 | 5,757 |
Maximum exposure to loss | 895,787 | 5,757 | 5,757 |
Total liabilities | — | — | — |
2025 | 2024 | |
$'000 | $'000 | |
Current | ||
Amounts owed by other JPMorganChase undertakings | ||
Trade debtors | ||
Corporation tax receivable | ||
2025 | 2024 | |
$'000 | $'000 | |
Debt and equity instruments | ||
Derivative receivables | ||
2025 | 2024 | |
$'000 | $'000 | |
Derivative payables | ||
2025 | 2024 | |
$'000 | $'000 | |
Amounts owed to other JPMorganChase undertakings | ||
Provision for liabilities | ||
Bank overdraft | ||
Other creditors | ||
2025 | 2024 | |
$'000 | $'000 | |
Issued and fully paid share capital | ||
1 (2024: nil) A ordinary shares of $1 each | ||
— | — |
Product/ instrument | Valuation methodology, inputs and assumptions | Classifications in the valuation hierarchy |
Derivatives | Exchange-traded derivatives that are actively traded and valued using the exchange price. | Level 1 |
Derivatives that are valued using models such as the Black Scholes option pricing model, simulation models, or a combination of models, that may use observable or unobservable valuation inputs as well as considering the contractual terms. | Level 2 or 3 | |
The key valuation inputs used will depend on the type of derivative and the nature of the underlying instruments and may include equity prices, commodity prices, interest rate yield curves, foreign exchange rates, volatilities, correlations, credit default swaps (“CDS”) spreads and recovery rates. Additionally, the credit quality of the counterparty and of the Company as well as market funding levels may also be considered. | ||
Equity, debt, and other securities | Quoted market prices | Level 1 |
In the absence of quoted market prices, securities are valued based on: • Observable market prices in a less liquid market or prices for similar securities • Relevant broker quotes • Discounted cash flows | Level 2 or 3 |
Level 1 | Level 2 | Level 3 | Total | |
$’000 | $’000 | $’000 | $’000 | |
At 31 December 2025 | ||||
Financial assets at fair value | ||||
Debt and equity instruments | ||||
Derivative receivables | — | |||
Total assets at fair value | ||||
Financial liabilities at fair value | ||||
Derivative payables | — | — | ||
— | — |
Level 1 | Level 2 | Level 3 | Total | |
$’000 | $’000 | $’000 | $’000 | |
At 31 December 2024 | ||||
Financial assets at fair value | ||||
Debt and equity instruments | ||||
Derivative receivables | — | |||
Total assets at fair value | ||||
Financial liabilities at fair value | ||||
Derivative payables | — | — | ||
— |
Product/instrument | Asset | Liability | |||||
At 31 December 2025 | $'000 | $'000 | $'000 | ||||
Debt and equity instruments | |||||||
Equity securities | 21,440 | — | 21,440 | Market comparables | Price | $0-$200 | $8 |
Total assets and liabilities | — |
Product/instrument | Asset | Liability | Net fair value | Principal valuation technique | Unobservable input | Range of input values | Weighted average |
At 31 December 2024 | $'000 | $'000 | $'000 | ||||
Debt and equity instruments | |||||||
Debt and equity securities | 73,573 | — | 73,573 | Price | $0-$85,000 | $2,067 | |
Commercial mortgage backed securities | 5,770 | — | 5,770 | Market comparable | Price | $0.004-$0.78 | $0.73 |
Total assets and liabilities | — |
Sensitivity analysis of valuations using unobservable inputs | Fair Value | Favourable change | Unfavourable change | ||
Asset | Liability | Net | Income statement | ||
At 31 December 2025 | $'000 | $'000 | $'000 | $'000 | $'000 |
Debt and equity instruments | |||||
Equity securities | 21,440 | — | 21,440 | 6,110 | (6,110) |
Total | — | 6,110 | (6,110) | ||
Sensitivity analysis of valuations using unobservable inputs | Fair Value | Favourable change | Unfavourable change | ||
Asset | Liability | Net | Income statement | ||
31 December 2024 | $'000 | $'000 | $'000 | $'000 | $'000 |
Debt and equity instruments | |||||
Debt and equity securities | 73,573 | — | 73,573 | 10,266 | (10,266) |
Commercial mortgage backed securities | 5,770 | — | 5,770 | 583 | (583) |
Total | — | 10,849 | (10,849) | ||
Debt and equity instruments | Derivative receivables | Total financial assets | |
$’000 | $’000 | $’000 | |
Financial Assets | |||
At 1 January 2025 | |||
Total loss recognised in income statement | ( | ( | ( |
Purchases | — | ||
Settlements | ( | — | ( |
Transfers in Level 3 | |||
Transfers out of Level 3 | ( | ( | ( |
At 31 December 2025 | |||
Change in unrealised loss related to financial instruments held at 31 December 2025 | ( | ( |
Debt and equity instruments | Derivative receivables | Total financial assets | ||
$’000 | $’000 | $’000 | ||
Financial Assets | ||||
At At 1 January 2024 | ||||
Total profit/(loss) recognised in income statement | ( | |||
Purchases | — | |||
Settlements | ( | — | ( | |
Transfers in Level 3 | ||||
Transfers out of Level 3 | ( | ( | ( | |
At 31 December 2024 | ||||
Change in unrealised gains related to financial instruments held at 31 December 2024 |